China Resources Pharmaceutical proposes articles of association amendments for regulatory alignment

China Resources Pharmaceutical Group Limited announced its board of directors has proposed amendments to the company's articles of association. These changes, set for November 27, 2025, aim to align with the latest legal and regulatory requirements concerning treasury shares and shareholder communication via website. This follows recent amendments to the Listing Rules of the Stock Exchange of Hong Kong Limited and the Companies Ordinance (Chapter 622 of the Laws of Hong Kong).

The proposed amendments also include consequential and other housekeeping adjustments. These changes require shareholder approval through a special resolution at a forthcoming extraordinary general meeting (EGM). A circular detailing the proposed amendments and a notice for the EGM will be dispatched to shareholders in due course.

The board of directors includes Mr. Bai Xiaosong as chairman and executive director, alongside Mr. Cheng Jie and Mr. Liu Changan as executive directors. Non-executive directors are Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan, and Mdm. Jiao Ruifang. Independent non-executive directors include Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian, and Mr. Shi Luwen.